SYNGENE · Healthcare · Diagnostics & Research
Composite scorecard: 39/100 — Quality 66 · Valuation 40 · Growth 23 · Momentum 0
| Share price | ₹417.60 |
| Market cap | ₹16,970 Cr |
| P/E ratio | 48.3 |
| P/B ratio | 3.6 |
| ROE | 6.6% |
| ROCE | 13.1% |
| Dividend yield | 0.30% |
| Book value | ₹117.84 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,739 Cr | ₹317 Cr | 25.0% |
| 2025 | ₹3,642 Cr | ₹496 Cr | 29.0% |
| 2024 | ₹3,489 Cr | ₹510 Cr | 29.0% |
| 2023 | ₹3,193 Cr | ₹464 Cr | 30.0% |
| 2022 | ₹2,604 Cr | ₹396 Cr | 29.0% |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i